<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Adult T-Cell Leukemia/Lymphoma - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .header-dates {
            display: flex;
            flex-wrap: wrap;
            gap: 10px;
            margin-top: 16px;
            padding-top: 12px;
            border-top: 1px solid rgba(255,255,255,0.22);
            position: relative;
        }

        .date-chip {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            background: rgba(255,255,255,0.14);
            border: 1px solid rgba(255,255,255,0.25);
            border-radius: 999px;
            padding: 5px 10px;
            font-size: 0.82rem;
        }

        .date-chip-label {
            font-weight: 600;
            opacity: 0.95;
        }

        .date-chip time {
            font-variant-numeric: tabular-nums;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Adult T-Cell Leukemia/Lymphoma</span>
        </nav>

        <header class="page-header">
            <h1>Adult T-Cell Leukemia/Lymphoma</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0019471" target="_blank">
                        MONDO:0019471
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">T-cell leukemia</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">T-cell lymphoma</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Adult T-cell leukemia/lymphoma (ATLL) is an aggressive peripheral T-cell neoplasm caused by Human T-lymphotropic Virus type 1 (HTLV-1) infection. The disease develops in approximately 2-5% of HTLV-1 carriers after a prolonged latency of decades. ATLL is endemic in southwestern Japan, the Caribbean, parts of South America, and sub-Saharan Africa. The HTLV-1 Tax oncoprotein is the primary driver of transformation, activating NF-kappaB and CREB pathways, inducing genomic instability, and impairing DNA repair. ATLL cells characteristically display a CD4+CD25+ regulatory T-cell phenotype with flower-shaped nuclear morphology.
            </p>
            
            
            <div class="header-dates">
                
                <span class="date-chip">
                    <span class="date-chip-label">Entry created</span>
                    <time datetime="2026-01-26T02:55:13Z">2026-01-26</time>
                </span>
                
                
                <span class="date-chip">
                    <span class="date-chip-label">Last updated</span>
                    <time datetime="2026-01-27T02:54:48Z">2026-01-27</time>
                </span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#histopathology">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Histopathology</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cancer</span>
                    
                    <span class="tag tag-classification">hematologic malignancy</span>
                    
                </div>
            </div>
            
            
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">ICD-O Morphology</div>
                <div class="tag-list">
                    <span class="tag tag-classification">Lymphoma</span>
                </div>
            </div>
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">4</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Acute ATLL
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Most aggressive form with leukemic presentation, hypercalcemia, organ infiltration, and opportunistic infections. Median survival is 6-10 months despite treatment. Characterized by high tumor burden and poor response to chemotherapy.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1751370" target="_blank">PMID:1751370</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"MST was 6.2 months for acute type"</div>
                
                
                <div class="evidence-explanation">Shimoyama classification study confirms acute ATLL has median survival of 6.2 months, supporting the poor prognosis described.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Lymphoma Type ATLL
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Presents with lymphadenopathy without significant blood involvement. May have better prognosis than acute form if responsive to chemotherapy. Less frequently associated with hypercalcemia.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1751370" target="_blank">PMID:1751370</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Lymphoma type, no lymphocytosis, 1% or less abnormal T-lymphocytes, and histologically-proven lymphadenopathy with or without extranodal lesions."</div>
                
                
                <div class="evidence-explanation">Shimoyama classification defines lymphoma type by lymphadenopathy without significant blood involvement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Chronic ATLL
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Indolent presentation with mild lymphocytosis and skin involvement. May remain stable for years before transforming to acute type. Better prognosis with median survival of several years.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1751370" target="_blank">PMID:1751370</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"24.3 months for chronic type"</div>
                
                
                <div class="evidence-explanation">Shimoyama study shows chronic type has median survival of 24.3 months, supporting the better prognosis described.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Smoldering ATLL
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Most indolent form with minimal lymphocytosis (&lt;5% abnormal cells) and often limited to skin lesions. May not require immediate treatment. Requires monitoring for transformation to aggressive disease.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1751370" target="_blank">PMID:1751370</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Smouldering type, 5% or more abnormal lymphocytes of T-cell nature in PB, normal lymphocyte level (less than 4 x 10(9)/l), no hypercalcaemia"</div>
                
                
                <div class="evidence-explanation">Shimoyama classification defines smoldering type by low abnormal cell counts and absence of hypercalcemia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">HTLV-1 Infection and Tax Oncoprotein Expression</div>
                
                <div class="item-desc">HTLV-1 preferentially infects CD4+ T cells and integrates into the host genome. The viral Tax protein is the primary driver of transformation, functioning as a transcriptional activator that hijacks multiple cellular pathways. Tax activates NF-kappaB, CREB/ATF, and AP-1 transcription factors, driving T-cell proliferation and survival.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        viral transcription
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0019083" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15129647" target="_blank">PMID:15129647</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"HTLV-1 causes 2 major diseases: adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy."</div>
                
                
                <div class="evidence-explanation">Abstract states HTLV-1 causes ATLL, supporting the infectious etiology.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15129647" target="_blank">PMID:15129647</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Tax is a 40-kDa phosphoprotein that is encoded by the pX region of the virus."</div>
                
                
                <div class="evidence-explanation">Abstract identifies Tax as a viral protein, supporting Tax oncoprotein expression.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Tax-Mediated NF-kappaB Activation</div>
                
                <div class="item-desc">Tax activates both canonical and non-canonical NF-kappaB pathways through direct interaction with IKK complex and NIK. Constitutive NF-kappaB activation drives expression of anti-apoptotic genes (BCL-XL, cIAP, survivin), cytokines (IL-2, IL-15), and cell cycle regulators, promoting T-cell survival and proliferation.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        positive regulation of NF-kappaB transcription factor activity
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0051092" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Genomic Instability and Accumulation of Mutations</div>
                
                <div class="item-desc">Tax impairs multiple DNA repair pathways including nucleotide excision repair, base excision repair, and double-strand break repair. This leads to accumulation of somatic mutations over the decades-long latency period. Tax also causes aneuploidy through centrosome amplification and mitotic checkpoint dysfunction.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        DNA damage response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006974" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Apoptosis Resistance</div>
                
                <div class="item-desc">Multiple mechanisms contribute to apoptosis resistance: NF-kappaB-mediated upregulation of BCL-XL and cIAP, Tax-mediated p53 inhibition, and HBZ-mediated enhancement of regulatory T-cell survival. This allows accumulation of cells with genomic abnormalities.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        apoptotic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006915" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Uncontrolled T-Cell Proliferation</div>
                
                <div class="item-desc">Combined effects of constitutive NF-kappaB activation, accumulated mutations, and apoptosis resistance result in clonal expansion of HTLV-1-infected T cells. ATLL cells acquire a CD4+CD25+FOXP3+ regulatory T-cell phenotype with immunosuppressive properties.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cell population proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008283" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        
        <div class="card" id="histopathology">
            <div class="card-header">
                <div class="card-icon" style="background: #ffedd5; color: #c2410c;">‚ú∂</div>
                <h2 class="card-title">Histopathology</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box histopathology-box">
                <div class="item-name">
                    T-Cell Lymphoproliferative Neoplasm
                    
                    <span class="histopathology-freq">VERY_FREQUENT</span>
                    
                </div>
                
                <div class="item-desc">Adult T-cell lymphoma/leukemia is a rare T-cell lymphoproliferative neoplasm.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28796966" target="_blank">PMID:28796966</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Adult T-cell lymphoma/leukemia (ATL) is a rare T-cell lymphoproliferative"</div>
                
                
                <div class="evidence-explanation">Abstract characterizes ATL as a rare T-cell lymphoproliferative neoplasm.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Uncontrolled_T_Cell_Proliferation[&#34;Uncontrolled T-Cell Proliferation&#34;]
    HTLV_1_Infection_and_Tax_Oncoprotein_Expression[&#34;HTLV-1 Infection and Tax Oncoprotein Expression&#34;]
    Genomic_Instability_and_Accumulation_of_Mutations[&#34;Genomic Instability and Accumulation of Mutations&#34;]
    Apoptosis_Resistance[&#34;Apoptosis Resistance&#34;]
    Tax_Mediated_NF_kappaB_Activation[&#34;Tax-Mediated NF-kappaB Activation&#34;]

    HTLV_1_Infection_and_Tax_Oncoprotein_Expression --&gt; Tax_Mediated_NF_kappaB_Activation
    HTLV_1_Infection_and_Tax_Oncoprotein_Expression --&gt; Genomic_Instability_and_Accumulation_of_Mutations
    Tax_Mediated_NF_kappaB_Activation --&gt; Apoptosis_Resistance
    Tax_Mediated_NF_kappaB_Activation --&gt; Uncontrolled_T_Cell_Proliferation
    Genomic_Instability_and_Accumulation_of_Mutations --&gt; Uncontrolled_T_Cell_Proliferation

    style Uncontrolled_T_Cell_Proliferation fill:#dbeafe
    style HTLV_1_Infection_and_Tax_Oncoprotein_Expression fill:#dbeafe
    style Genomic_Instability_and_Accumulation_of_Mutations fill:#dbeafe
    style Apoptosis_Resistance fill:#dbeafe
    style Tax_Mediated_NF_kappaB_Activation fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Blood<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Cardiovascular<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Digestive<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Immune<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Integument<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-6">Metabolism<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Blood
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Leukocytosis
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001974" target="_blank">
                                Increased total leukocyte count
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001974)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Lymphadenopathy
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002716" target="_blank">
                                Lymphadenopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002716)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Splenomegaly
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001744" target="_blank">
                                Splenomegaly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001744)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hepatomegaly
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002240" target="_blank">
                                Hepatomegaly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002240)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Immune
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Opportunistic Infections
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002719" target="_blank">
                                Recurrent infections
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002719)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Integument
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Skin Lesions
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0011121" target="_blank">
                                Abnormal skin morphology
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0011121)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-6">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Metabolism
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypercalcemia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003072" target="_blank">
                                Hypercalcemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003072)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24714244" target="_blank">PMID:24714244</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypercalcemia occurs in about 70% of patients with acute adult T cell leukemia."</div>
                
                
                <div class="evidence-explanation">Review abstract reports hypercalcemia frequency in acute adult T cell leukemia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HTLV-1 Tax
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Viral Oncogene)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HTLV-1 HBZ
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Viral Oncogene)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TP53
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Mutation)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CCR4
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Gain of Function Mutation)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Chemotherapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000647" target="_blank">
                            MAXO:0000647
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Intensive combination chemotherapy regimens including CHOP-like protocols or more intensive regimens (VCAP-AMP-VECP). Response rates are modest and duration is typically short in aggressive disease.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22042945" target="_blank">PMID:22042945</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The overall response rate ranged from 49% with chemotherapy alone to 81% with combined first-line therapy (chemotherapy with concurrent/sequential ZDV/IFN-Œ±)."</div>
                
                
                <div class="evidence-explanation">Study shows chemotherapy alone achieves 49% response rate in aggressive ATLL, supporting modest efficacy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Mogamulizumab
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Anti-CCR4 monoclonal antibody approved for relapsed/refractory ATLL. CCR4 is highly expressed on ATLL cells. Provides activity in patients with CCR4 mutations who have particularly high expression.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30573506" target="_blank">PMID:30573506</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"mogamulizumab treatment resulted in 11% cORR, with a tolerable safety profile."</div>
                
                
                <div class="evidence-explanation">International phase II trial showed mogamulizumab demonstrated responses in relapsed/refractory ATLL where chemotherapy showed no activity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Allogeneic Stem Cell Transplantation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000747" target="_blank">
                            MAXO:0000747
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Only potentially curative treatment for ATLL. Graft-versus-ATLL effect contributes to efficacy. Reserved for younger patients with aggressive disease who achieve remission. Long-term survival of 30-40% in selected patients.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30573506" target="_blank">PMID:30573506</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Allogeneic stem cell transplantation (allo-SCT) can significantly prolong survival, but there are few appropriate candidates"</div>
                
                
                <div class="evidence-explanation">Study confirms allo-SCT prolongs survival but notes limited candidates due to age and prior treatment response requirements.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Interferon-alpha and Zidovudine
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Combination of interferon-alpha and zidovudine (AZT) shows activity, particularly in leukemic subtypes. May be combined with or followed by chemotherapy. Mechanism involves both antiviral and pro-apoptotic effects.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22042945" target="_blank">PMID:22042945</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Use of ZDV/IFN-Œ± at any time prolonged survival in acute (P &lt; .001) and lymphoma ATLL (P &lt; .001) and was the sole factor associated with reduction in risk of death in aggressive ATLL"</div>
                
                
                <div class="evidence-explanation">UK study demonstrated ZDV/IFN-Œ± significantly prolonged survival in both acute and lymphoma ATLL subtypes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    HTLV-1 Antibodies
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    HTLV-1 Proviral Load
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Soluble IL-2 Receptor (sIL-2R)
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Adult T-Cell Leukemia/Lymphoma
creation_date: &#39;2026-01-26T02:55:13Z&#39;
updated_date: &#39;2026-01-27T02:54:48Z&#39;
description: &gt;-
  Adult T-cell leukemia/lymphoma (ATLL) is an aggressive peripheral T-cell neoplasm
  caused by Human T-lymphotropic Virus type 1 (HTLV-1) infection. The disease develops
  in approximately 2-5% of HTLV-1 carriers after a prolonged latency of decades.
  ATLL is endemic in southwestern Japan, the Caribbean, parts of South America,
  and sub-Saharan Africa. The HTLV-1 Tax oncoprotein is the primary driver of
  transformation, activating NF-kappaB and CREB pathways, inducing genomic instability,
  and impairing DNA repair. ATLL cells characteristically display a CD4+CD25+ regulatory
  T-cell phenotype with flower-shaped nuclear morphology.
categories:
- Hematologic Malignancy
- T-Cell Lymphoma
- Virus-Associated Cancer
parents:
- T-cell leukemia
- T-cell lymphoma
has_subtypes:
- name: Acute ATLL
  description: &gt;-
    Most aggressive form with leukemic presentation, hypercalcemia, organ
    infiltration, and opportunistic infections. Median survival is 6-10 months
    despite treatment. Characterized by high tumor burden and poor response
    to chemotherapy.
  evidence:
  - reference: PMID:1751370
    supports: SUPPORT
    snippet: &gt;-
      MST was 6.2 months for acute type
    explanation: &gt;-
      Shimoyama classification study confirms acute ATLL has median survival
      of 6.2 months, supporting the poor prognosis described.
- name: Lymphoma Type ATLL
  description: &gt;-
    Presents with lymphadenopathy without significant blood involvement.
    May have better prognosis than acute form if responsive to chemotherapy.
    Less frequently associated with hypercalcemia.
  evidence:
  - reference: PMID:1751370
    supports: SUPPORT
    snippet: &gt;-
      Lymphoma type, no lymphocytosis, 1% or less abnormal T-lymphocytes, and
      histologically-proven lymphadenopathy with or without extranodal lesions.
    explanation: &gt;-
      Shimoyama classification defines lymphoma type by lymphadenopathy without
      significant blood involvement.
- name: Chronic ATLL
  description: &gt;-
    Indolent presentation with mild lymphocytosis and skin involvement.
    May remain stable for years before transforming to acute type.
    Better prognosis with median survival of several years.
  evidence:
  - reference: PMID:1751370
    supports: SUPPORT
    snippet: &gt;-
      24.3 months for chronic type
    explanation: &gt;-
      Shimoyama study shows chronic type has median survival of 24.3 months,
      supporting the better prognosis described.
- name: Smoldering ATLL
  description: &gt;-
    Most indolent form with minimal lymphocytosis (&lt;5% abnormal cells) and
    often limited to skin lesions. May not require immediate treatment.
    Requires monitoring for transformation to aggressive disease.
  evidence:
  - reference: PMID:1751370
    supports: SUPPORT
    snippet: &gt;-
      Smouldering type, 5% or more abnormal lymphocytes of T-cell nature in PB,
      normal lymphocyte level (less than 4 x 10(9)/l), no hypercalcaemia
    explanation: &gt;-
      Shimoyama classification defines smoldering type by low abnormal cell
      counts and absence of hypercalcemia.
infectious_agent:
- name: Human T-Lymphotropic Virus Type 1 (HTLV-1)
  infectious_agent_term:
    preferred_term: Human T-cell leukemia virus type I
    term:
      id: NCBITaxon:11908
      label: Human T-cell leukemia virus type I
  description: &gt;-
    HTLV-1 is a deltaretrovirus that infects CD4+ T cells. Transmission occurs
    through breastfeeding, sexual contact, blood transfusion, and injection drug
    use. After infection, HTLV-1 integrates into the host genome and establishes
    lifelong persistent infection. The viral Tax protein is the major transforming
    factor, activating NF-kappaB, inducing genomic instability, and promoting
    T-cell proliferation. HBZ (HTLV-1 basic leucine zipper factor) expressed from
    the antisense strand also contributes to leukemogenesis.
  evidence:
  - reference: PMID:41553980
    supports: SUPPORT
    snippet: &#34;HTLV-1 is a retrovirus associated with adult T cell leukemia/lymphoma (ATL) and inflammatory diseases, including HTLV-1-associated myelopathy (HAM) and HTLV-1-associated bronchopneumonopathy (HAB).&#34;
    explanation: This abstract explicitly links HTLV-1 to adult T-cell leukemia/lymphoma, supporting the infectious etiology.
pathophysiology:
- name: HTLV-1 Infection and Tax Oncoprotein Expression
  description: &gt;-
    HTLV-1 preferentially infects CD4+ T cells and integrates into the host genome.
    The viral Tax protein is the primary driver of transformation, functioning as
    a transcriptional activator that hijacks multiple cellular pathways. Tax activates
    NF-kappaB, CREB/ATF, and AP-1 transcription factors, driving T-cell proliferation
    and survival.
  evidence:
  - reference: PMID:15129647
    supports: SUPPORT
    snippet: &#34;HTLV-1 causes 2 major diseases: adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy.&#34;
    explanation: &#34;Abstract states HTLV-1 causes ATLL, supporting the infectious etiology.&#34;
  - reference: PMID:15129647
    supports: SUPPORT
    snippet: &#34;Tax is a 40-kDa phosphoprotein that is encoded by the pX region of the virus.&#34;
    explanation: &#34;Abstract identifies Tax as a viral protein, supporting Tax oncoprotein expression.&#34;
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: viral transcription
    term:
      id: GO:0019083
      label: viral transcription
  downstream:
  - target: Tax-Mediated NF-kappaB Activation
    description: Tax constitutively activates NF-kappaB signaling
  - target: Genomic Instability and Accumulation of Mutations
    description: Tax impairs DNA repair and induces genomic instability
- name: Tax-Mediated NF-kappaB Activation
  description: &gt;-
    Tax activates both canonical and non-canonical NF-kappaB pathways through
    direct interaction with IKK complex and NIK. Constitutive NF-kappaB activation
    drives expression of anti-apoptotic genes (BCL-XL, cIAP, survivin), cytokines
    (IL-2, IL-15), and cell cycle regulators, promoting T-cell survival and
    proliferation.
  biological_processes:
  - preferred_term: positive regulation of NF-kappaB transcription factor activity
    modifier: INCREASED
    term:
      id: GO:0051092
      label: positive regulation of NF-kappaB transcription factor activity
  downstream:
  - target: Apoptosis Resistance
    description: NF-kappaB activates anti-apoptotic gene expression
  - target: Uncontrolled T-Cell Proliferation
    description: NF-kappaB and cytokine signaling drive proliferation
- name: Genomic Instability and Accumulation of Mutations
  description: &gt;-
    Tax impairs multiple DNA repair pathways including nucleotide excision repair,
    base excision repair, and double-strand break repair. This leads to accumulation
    of somatic mutations over the decades-long latency period. Tax also causes
    aneuploidy through centrosome amplification and mitotic checkpoint dysfunction.
  biological_processes:
  - preferred_term: DNA damage response
    modifier: DECREASED
    term:
      id: GO:0006974
      label: DNA damage response
  downstream:
  - target: Uncontrolled T-Cell Proliferation
    description: Accumulated mutations in growth regulatory genes promote transformation
- name: Apoptosis Resistance
  description: &gt;-
    Multiple mechanisms contribute to apoptosis resistance: NF-kappaB-mediated
    upregulation of BCL-XL and cIAP, Tax-mediated p53 inhibition, and HBZ-mediated
    enhancement of regulatory T-cell survival. This allows accumulation of cells
    with genomic abnormalities.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
- name: Uncontrolled T-Cell Proliferation
  description: &gt;-
    Combined effects of constitutive NF-kappaB activation, accumulated mutations,
    and apoptosis resistance result in clonal expansion of HTLV-1-infected T cells.
    ATLL cells acquire a CD4+CD25+FOXP3+ regulatory T-cell phenotype with
    immunosuppressive properties.
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
histopathology:
- name: T-Cell Lymphoproliferative Neoplasm
  finding_term:
    preferred_term: Adult T-Cell Leukemia/Lymphoma
    term:
      id: NCIT:C3184
      label: Adult T-Cell Leukemia/Lymphoma
  frequency: VERY_FREQUENT
  description: Adult T-cell lymphoma/leukemia is a rare T-cell lymphoproliferative neoplasm.
  evidence:
  - reference: PMID:28796966
    supports: SUPPORT
    snippet: &#34;Adult T-cell lymphoma/leukemia (ATL) is a rare T-cell lymphoproliferative&#34;
    explanation: Abstract characterizes ATL as a rare T-cell lymphoproliferative neoplasm.

phenotypes:
- category: Hematologic
  name: Leukocytosis
  frequency: VERY_FREQUENT
  diagnostic: true
  description: &gt;-
    Elevated white blood cell count with characteristic &#34;flower cells&#34; showing
    multilobated nuclei. Peripheral blood involvement is prominent in acute and
    chronic forms.
  phenotype_term:
    preferred_term: Increased total leukocyte count
    term:
      id: HP:0001974
      label: Increased total leukocyte count
- category: Lymphatic
  name: Lymphadenopathy
  frequency: VERY_FREQUENT
  description: &gt;-
    Generalized lymphadenopathy is common, particularly prominent in
    lymphoma-type ATLL.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
- category: Metabolic
  name: Hypercalcemia
  frequency: FREQUENT
  diagnostic: true
  description: &gt;-
    Hypercalcemia occurs in up to 70% of acute ATLL cases due to ATLL cell
    production of PTHrP (parathyroid hormone-related protein) and osteoclast-
    activating cytokines. Can be severe and life-threatening.
  evidence:
  - reference: PMID:24714244
    supports: SUPPORT
    snippet: &#34;Hypercalcemia occurs in about 70% of patients with acute adult T cell leukemia.&#34;
    explanation: &#34;Review abstract reports hypercalcemia frequency in acute adult T cell leukemia.&#34;
  phenotype_term:
    preferred_term: Hypercalcemia
    term:
      id: HP:0003072
      label: Hypercalcemia
- category: Dermatologic
  name: Skin Lesions
  frequency: FREQUENT
  description: &gt;-
    Skin involvement with erythematous papules, nodules, plaques, or
    erythroderma. Prominent in smoldering and chronic forms. May resemble
    mycosis fungoides.
  phenotype_term:
    preferred_term: Abnormal skin morphology
    term:
      id: HP:0011121
      label: Abnormal skin morphology
- category: Abdominal
  name: Hepatomegaly
  frequency: FREQUENT
  description: &gt;-
    Liver enlargement from leukemic infiltration, common in acute ATLL.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
- category: Abdominal
  name: Splenomegaly
  frequency: FREQUENT
  description: &gt;-
    Splenic enlargement from leukemic infiltration.
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
- category: Infectious
  name: Opportunistic Infections
  frequency: FREQUENT
  description: &gt;-
    ATLL cells have regulatory T-cell properties causing profound
    immunosuppression. Opportunistic infections including Pneumocystis,
    Strongyloides, and fungal infections are common and major causes of death.
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
biochemical:
- name: HTLV-1 Antibodies
  notes: &gt;-
    Seropositivity for HTLV-1 antibodies is required for diagnosis. ELISA
    screening followed by Western blot confirmation.
- name: HTLV-1 Proviral Load
  notes: &gt;-
    Quantification of HTLV-1 proviral DNA by PCR. High proviral load is
    associated with increased risk of ATLL development.
- name: Soluble IL-2 Receptor (sIL-2R)
  notes: &gt;-
    Markedly elevated sIL-2R reflects high tumor burden and T-cell activation.
    Useful for monitoring disease activity.
genetic:
- name: HTLV-1 Tax
  association: Viral Oncogene
  notes: &gt;-
    Tax is the major HTLV-1 transforming protein. Activates NF-kappaB, CREB,
    and AP-1 pathways; induces genomic instability; inhibits DNA repair;
    and dysregulates cell cycle. Tax expression is often lost in established
    ATLL due to promoter methylation, suggesting its role is primarily in
    early transformation.
- name: HTLV-1 HBZ
  association: Viral Oncogene
  notes: &gt;-
    HBZ (HTLV-1 basic leucine zipper factor) is expressed from the antisense
    strand and maintained in all ATLL cells. Promotes T-cell proliferation
    and regulatory T-cell phenotype. Contributes to transformation
    independently of Tax.
- name: TP53
  association: Somatic Mutation
  notes: &gt;-
    TP53 mutations occur in approximately 20-40% of aggressive ATLL and
    are associated with poor prognosis. More common in acute than
    indolent forms.
- name: CCR4
  association: Gain of Function Mutation
  notes: &gt;-
    CCR4 mutations occur in approximately 25% of cases and result in
    receptor stabilization and enhanced signaling. Target of mogamulizumab
    therapy.
treatments:
- name: Chemotherapy
  description: &gt;-
    Intensive combination chemotherapy regimens including CHOP-like protocols
    or more intensive regimens (VCAP-AMP-VECP). Response rates are modest
    and duration is typically short in aggressive disease.
  evidence:
  - reference: PMID:22042945
    supports: SUPPORT
    snippet: &gt;-
      The overall response rate ranged from 49% with chemotherapy alone to 81%
      with combined first-line therapy (chemotherapy with concurrent/sequential
      ZDV/IFN-Œ±).
    explanation: &gt;-
      Study shows chemotherapy alone achieves 49% response rate in aggressive
      ATLL, supporting modest efficacy.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
- name: Mogamulizumab
  description: &gt;-
    Anti-CCR4 monoclonal antibody approved for relapsed/refractory ATLL.
    CCR4 is highly expressed on ATLL cells. Provides activity in patients
    with CCR4 mutations who have particularly high expression.
  evidence:
  - reference: PMID:30573506
    supports: SUPPORT
    snippet: &gt;-
      mogamulizumab treatment resulted in 11% cORR, with a tolerable safety
      profile.
    explanation: &gt;-
      International phase II trial showed mogamulizumab demonstrated responses
      in relapsed/refractory ATLL where chemotherapy showed no activity.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Allogeneic Stem Cell Transplantation
  description: &gt;-
    Only potentially curative treatment for ATLL. Graft-versus-ATLL effect
    contributes to efficacy. Reserved for younger patients with aggressive
    disease who achieve remission. Long-term survival of 30-40% in selected
    patients.
  evidence:
  - reference: PMID:30573506
    supports: SUPPORT
    snippet: &gt;-
      Allogeneic stem cell transplantation (allo-SCT) can significantly prolong
      survival, but there are few appropriate candidates
    explanation: &gt;-
      Study confirms allo-SCT prolongs survival but notes limited candidates
      due to age and prior treatment response requirements.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
- name: Interferon-alpha and Zidovudine
  description: &gt;-
    Combination of interferon-alpha and zidovudine (AZT) shows activity,
    particularly in leukemic subtypes. May be combined with or followed
    by chemotherapy. Mechanism involves both antiviral and pro-apoptotic
    effects.
  evidence:
  - reference: PMID:22042945
    supports: SUPPORT
    snippet: &gt;-
      Use of ZDV/IFN-Œ± at any time prolonged survival in acute (P &lt; .001) and
      lymphoma ATLL (P &lt; .001) and was the sole factor associated with
      reduction in risk of death in aggressive ATLL
    explanation: &gt;-
      UK study demonstrated ZDV/IFN-Œ± significantly prolonged survival in both
      acute and lymphoma ATLL subtypes.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
disease_term:
  preferred_term: adult T-cell leukemia/lymphoma
  term:
    id: MONDO:0019471
    label: adult T-cell leukemia/lymphoma

classifications:
  icdo_morphology:
    classification_value: Lymphoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: hematologic malignancy
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Adult_T_Cell_Leukemia_Lymphoma.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>